252 related articles for article (PubMed ID: 19397268)
1. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
Wang GN; Reinkensmeier G; Zhang SW; Zhou J; Zhang LR; Zhang LH; Butters TD; Ye XS
J Med Chem; 2009 May; 52(10):3146-9. PubMed ID: 19397268
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.
Wang GN; Twigg G; Butters TD; Zhang S; Zhang L; Zhang LH; Ye XS
Org Biomol Chem; 2012 Apr; 10(15):2923-7. PubMed ID: 22286559
[TBL] [Abstract][Full Text] [Related]
3. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
[TBL] [Abstract][Full Text] [Related]
4. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
5. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.
Joosten A; Decroocq C; de Sousa J; Schneider JP; Etamé E; Bodlenner A; Butters TD; Compain P
Chembiochem; 2014 Jan; 15(2):309-19. PubMed ID: 24375964
[TBL] [Abstract][Full Text] [Related]
6. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR
Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081
[TBL] [Abstract][Full Text] [Related]
7. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
[TBL] [Abstract][Full Text] [Related]
8. Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease.
Kato A; Nakagome I; Sato K; Yamamoto A; Adachi I; Nash RJ; Fleet GW; Natori Y; Watanabe Y; Imahori T; Yoshimura Y; Takahata H; Hirono S
Org Biomol Chem; 2016 Jan; 14(3):1039-48. PubMed ID: 26633162
[TBL] [Abstract][Full Text] [Related]
9. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
[TBL] [Abstract][Full Text] [Related]
10. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.
Parmeggiani C; Catarzi S; Matassini C; D'Adamio G; Morrone A; Goti A; Paoli P; Cardona F
Chembiochem; 2015 Sep; 16(14):2054-64. PubMed ID: 26376302
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
Rasmussen TS; Allman S; Twigg G; Butters TD; Jensen HH
Bioorg Med Chem Lett; 2011 Mar; 21(5):1519-22. PubMed ID: 21292481
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease.
Compain P; Martin OR; Boucheron C; Godin G; Yu L; Ikeda K; Asano N
Chembiochem; 2006 Sep; 7(9):1356-9. PubMed ID: 16871601
[No Abstract] [Full Text] [Related]
14. Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease.
Laigre E; Hazelard D; Casas J; Serra-Vinardell J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Compain P
Carbohydr Res; 2016 Jun; 429():98-104. PubMed ID: 27063390
[TBL] [Abstract][Full Text] [Related]
15. Exploring substituent diversity on pyrrolidine-aryltriazole iminosugars: Structural basis of β-glucocerebrosidase inhibition.
Martínez-Bailén M; Carmona AT; Patterson-Orazem AC; Lieberman RL; Ide D; Kubo M; Kato A; Robina I; Moreno-Vargas AJ
Bioorg Chem; 2019 May; 86():652-664. PubMed ID: 30825709
[TBL] [Abstract][Full Text] [Related]
16. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
[TBL] [Abstract][Full Text] [Related]
17. Probing the Inhibitor versus Chaperone Properties of sp²-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease.
Mena-Barragán T; García-Moreno MI; Sevšek A; Okazaki T; Nanba E; Higaki K; Martin NI; Pieters RJ; Fernández JMG; Mellet CO
Molecules; 2018 Apr; 23(4):. PubMed ID: 29673163
[TBL] [Abstract][Full Text] [Related]
18. Conformationally-locked N-glycosides with selective β-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.
Castilla J; Rísquez R; Cruz D; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
J Med Chem; 2012 Aug; 55(15):6857-65. PubMed ID: 22762530
[TBL] [Abstract][Full Text] [Related]
19. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR
ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
[TBL] [Abstract][Full Text] [Related]
20. Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease.
Borie-Guichot M; Lan Tran M; Garcia V; Oukhrib A; Rodriguez F; Turrin CO; Levade T; Génisson Y; Ballereau S; Dehoux C
Bioorg Chem; 2024 May; 146():107295. PubMed ID: 38513326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
